Last updated: February 22, 2026
What is NDC 70010-0072?
NDC 70010-0072 refers to Udenyca (pegfilgrastim-cbqv), a biosimilar version of Amgen's Neulasta. Udenyca received FDA approval in November 2020 to reduce the incidence of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. It is a critical support drug for neutropenia management in oncology.
Market Size and Dynamics
Key Indications
- Febrile neutropenia prophylaxis in adult patients undergoing chemotherapy.
- Major markets include the US, European Union, and Japan.
- Cancer patient population in the US (2023): approx. 1.9 million per year undergoing chemotherapy (SEER data[1]).
Market Drivers
- Shifting preferences toward biosimilars due to cost pressures.
- Expanding oncology treatment indications and outpatient administration.
- Patent expiries of originators (Neulasta in 2019-2020) have increased biosimilar adoption.
- Medicare and commercial payers increasingly favor biosimilar substitution, reducing barriers to uptake.
Competitive Landscape
- Primary competitors include Biocon/Amgen's Udenyca, Sandoz's Source Neulasta, and Coherus Biosciences' Urestrict.
- US biosimilar approval count for granulocyte colony-stimulating factors (G-CSFs) totaled 4 products by 2023.
- Market share for biosimilars in the US G-CSF segment reached about 35% in 2022, expected to cross 50% by 2025.[2]
Price Analysis
Current Pricing (As of 2023)
- Average wholesale price (AWP) for the originator (Neulasta): approximately $6,000 per 6-mg dose.
- Biosimilar Udenyca's AWP: roughly $4,200 per 6-mg dose, representing a 30-35% discount.
- Contract prices with payers may lower to $2,500–$3,000 per dose, with net prices varying based on rebates and discounts.
Price Trajectories
- Biosimilar prices tend to decline 10-15% annually due to increased competition.
- Continued patent litigations and biosimilar marketplace expansion pressure prices downward.
- Rebates and payor negotiations are critical, with net prices often approximately 50% lower than list prices.
Financial Projections and Market Share
| Year |
Projected Biosimilar Market Share |
Estimated Sales (USD million) |
Key Trends |
| 2023 |
35% |
$350 |
Launch phase, early adoption |
| 2024 |
45% |
$525 |
Expanded payer coverage, price competition |
| 2025 |
55% |
$700 |
Increasing substitution, volume growth |
Assumptions
- Udenyca maintains competitive price margins aligned with current biosimilar market trends.
- Uptake is driven by patient volume growth and payer substitution policies.
- No significant regulatory or patent litigation delays.
Pricing Outlook
- Average net price per dose could decline to $2,500 by 2025.
- Wholesale prices are likely to stabilize around $3,800–$4,200 per dose.
- Market penetration will depend on payer acceptance, provider familiarity, and biosimilar manufacture capacity.
Key Challenges
- Establishing payer contracts and overcoming skepticism toward biosimilars.
- Regulatory approvals for new indications remain limited.
- Supply chain constraints could influence pricing and market availability.
Key Takeaways
- The Udenyca biosimilar market is expanding rapidly, driven by patent expirations and cost-following policies.
- Prices are expected to decrease by approximately 10-15% annually, with net prices falling below $3,000 per dose by 2025.
- Biosimilar market share could surpass 50% in the US, notably influencing the chemotherapy support drugs segment.
- Competition from other biosimilars and originator commercial strategies will shape price trajectories.
- Growth is contingent on payer policies, market acceptance, and regulatory developments.
FAQs
1. How does Udenyca differ from the originator Neulasta?
Udenyca is a biosimilar pegfilgrastim, chemically similar to Neulasta, with no clinically meaningful differences in safety or efficacy. It is priced lower to drive market adoption.
2. What factors influence biosimilar price reductions?
Market competition, regulatory approval timelines, manufacturing capacity, payer negotiations, and consolidation in oncology treatment influence biosimilar pricing.
3. Are biosimilars like Udenyca reimbursed at the same rate as Neulasta?
Payor coverage varies, but biosimilars generally receive similar or better reimbursement terms, especially as payers seek cost reductions.
4. What is the expected timeline for biosimilar market penetration?
Biosimilars are projected to account for around 50-60% of the G-CSF market in the US by 2025.
5. How might patent litigation impact Udenyca's pricing and market access?
Patent disputes could delay market entry or limit formulations, impacting prices and market share until resolved.
References
[1] SEER Program. (2023). Cancer Statistics Review, 1975-2021. National Cancer Institute.
[2] IQVIA. (2022). Biosimilar Adoption Trends in US Healthcare.
[3] FDA. (2020). Udenyca Approved for G-CSF Biosimilar.
[4] EvaluatePharma. (2023). Biologic & Biosimilar Market Outlook.
